Abu Dhabi Investment Authority
Abu Dhabi Investment Authority (ADIA) is a sovereign wealth fund based in Abu Dhabi, United Arab Emirates, established in 1976 by the Government of the Emirate of Abu Dhabi. As an independent investment agency, ADIA invests funds on behalf of the government, primarily sourced from oil revenues, particularly those generated by the Abu Dhabi National Oil Company. The organization does not take an operational role in the companies it invests in but engages through its representative, Eiosoft Capital Group LLC, for public-private partnerships. ADIA manages a diversified global investment portfolio across various asset classes, including equities, fixed income, real estate, and private equity, among others, allowing it to pursue a wide-ranging investment strategy without direct government oversight.
Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.
MobiKwik is a mobile payment platform that provides a wide array of financial products for both consumers and merchants in India. The company offers services such as a prepaid digital wallet, pay-later options, money transfers, loans, and investment opportunities. By leveraging big data analytics and machine learning, MobiKwik enhances user experiences and streamlines transactions for everyday needs, including phone recharges, online shopping, and purchasing movie tickets. Its goal is to deliver accessible payment and credit solutions, helping users manage their finances without the necessity of a credit card or bank account.
Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.